The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,301,146 in first-year total cost, median $650,573.
Most frequent study sections
- Special Emphasis Panel[ZEY1 VSN (01)]2
Most frequent institutions
- DANA-FARBER CANCER INST1
- WASHINGTON UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency1UG1EY027726-01 | RITZ, JEROME | DANA-FARBER CANCER INST, MA | $621,211 | ZEY1 |
| 2015 | Ocular Hypertension Treatment Study 20-Year Follow-up: Resource Center Grant1UG1EY025183-01 | KASS, MICHAEL A | WASHINGTON UNIVERSITY, MO | $679,935 | ZEY1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.